Tilray Brands (NASDAQ:TLRY) Trading Up 8.1% – Here’s What Happened

Tilray Brands, Inc. (NASDAQ:TLRY)’s stock price rose 8.1% during mid-day trading on Wednesday . The company traded as high as $4.86 and last traded at $4.83. Approximately 5,162,259 shares were traded during mid-day trading, an increase of 20% from the average session volume of 4,302,896 shares. The stock had previously closed at $4.47.

Key Headlines Impacting Tilray Brands

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: A sector-wide rebound lifted Tilray alongside Canopy Growth and Aurora Cannabis, suggesting investors were buying depressed cannabis stocks. However, the rally has not reversed the company’s broader weakness, with TLRY still down sharply for the year. Tilray Jumps 6%, Canopy Growth Climbs 3%, Aurora Cannabis Gains 4%
• Positive Sentiment: Tilray Medical welcomed new German guidance that provides more practical direction for prescribing standardized full-spectrum cannabis extracts. A clearer medical-cannabis framework could support physician adoption, patient access and Tilray’s European medical business. Tilray Medical Welcomes Progress in Germany’s Medical Cannabis Framework
• Positive Sentiment: Tilray’s UK expansion is being viewed as a potential growth catalyst, while its international operations and consumer brands provide investors with exposure beyond Canada’s challenged recreational market. Could Tilray Brands Gain From Its UK Push?
• Neutral Sentiment: BrewDog, Tilray’s craft-beer subsidiary, announced its 2026 Advent Calendar. The product supports brand visibility and seasonal sales but is unlikely to materially affect near-term valuation. BrewDog Unwraps Its 2026 Advent Calendar
• Negative Sentiment: Analysts and commentators caution that Tilray’s underlying challenges remain unresolved, including an uncertain cannabis market, regulatory complexity and weak profitability. The latest rally therefore looks primarily sentiment-driven rather than evidence of a fundamental turnaround. The Cannabis Story Is Getting Complicated

Wall Street Analysts Forecast Growth

TLRY has been the topic of several recent research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Tilray Brands in a report on Friday, August 7th. TD Securities upgraded Tilray Brands to a “strong-buy” rating in a research note on Friday, July 31st. TD Cowen lowered their price objective on Tilray Brands from $7.00 to $5.00 and set a “buy” rating for the company in a research report on Tuesday, July 14th. Finally, Wall Street Zen lowered shares of Tilray Brands from a “hold” rating to a “sell” rating in a research note on Saturday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $11.00.

Tilray Brands Trading Up 8.1%

The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.37 and a current ratio of 2.21. The company’s 50-day moving average price is $4.50 and its 200-day moving average price is $5.86. The firm has a market capitalization of $657.85 million, a PE ratio of -4.47 and a beta of 1.90.

Tilray Brands (NASDAQ:TLRY) last posted its earnings results on Tuesday, July 28th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.42). Tilray Brands had a negative net margin of 13.11% and a negative return on equity of 7.76%. The business had revenue of $281.71 million during the quarter, compared to analysts’ expectations of $246.30 million. On average, sell-side analysts expect that Tilray Brands, Inc. will post -0.4 earnings per share for the current year.

Insider Activity

In other Tilray Brands news, CFO Carl A. Merton acquired 10,000 shares of the stock in a transaction dated Tuesday, August 4th. The stock was acquired at an average cost of $4.62 per share, with a total value of $46,200.00. Following the transaction, the chief financial officer owned 139,753 shares in the company, valued at $645,658.86. The trade was a 7.71% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last ninety days, insiders bought 15,000 shares of company stock worth $69,225. Corporate insiders own 0.84% of the company’s stock.

Institutional Investors Weigh In On Tilray Brands

Institutional investors have recently added to or reduced their stakes in the business. Hilton Head Capital Partners LLC acquired a new position in Tilray Brands in the fourth quarter valued at approximately $38,000. Cerity Partners LLC raised its holdings in Tilray Brands by 98.5% during the second quarter. Cerity Partners LLC now owns 92,560 shares of the company’s stock worth $38,000 after purchasing an additional 45,929 shares in the last quarter. Marex Group plc acquired a new stake in Tilray Brands during the second quarter worth approximately $40,000. Hilton Capital Management LLC purchased a new stake in shares of Tilray Brands during the 2nd quarter worth approximately $41,000. Finally, Deutsche Bank AG purchased a new stake in shares of Tilray Brands during the 2nd quarter worth approximately $44,000. Hedge funds and other institutional investors own 9.35% of the company’s stock.

Tilray Brands Company Profile

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.